Editor-in-Chief:
Gerald Litwack, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
Description
The discovery of TRAIL (TNF Related Apoptosis Inducing Ligand), also referred to as Apo-2, is in an era of intense research because TRAIL
induces many cancer cells to undergo programmed cell death (apoptosis), while having no effect on normal cells. This important protein
deserves extensive review at a formative time in the devlopement of our knowledge concerning its mechanism of action and the ways in
which it can be used as a cancer chemotherapeutic agent. Consequently, this voume reviews the current status of research on TRAIL.
Included in series
Vitamins and Hormones
Audience:
Molecular biologists, cellular biologists, & biochemists
